Cargando…
B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin
INTRODUCTION: Recently, several studies assessing the clinical efficacy of rituximab (RTX) in systemic sclerosis (SSc) have reported encouraging results. We aimed at exploring whether RTX exerts its beneficial effects on fibrosis through attenuation of platelet-derived growth factor receptor (PDGFR)...
Autores principales: | Daoussis, Dimitrios, Tsamandas, Athanassios C, Liossis, Stamatis-Nick C, Antonopoulos, Ioannis, Karatza, Elli, Yiannopoulos, Georgios, Andonopoulos, Andrew P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446529/ https://www.ncbi.nlm.nih.gov/pubmed/22697462 http://dx.doi.org/10.1186/ar3879 |
Ejemplares similares
-
B-Cell Depletion Therapy in Systemic Sclerosis: Experimental Rationale and Update on Clinical Evidence
por: Daoussis, Dimitrios, et al.
Publicado: (2011) -
B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis
por: Daoussis, Dimitrios, et al.
Publicado: (2016) -
Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
por: Daoussis, Dimitrios, et al.
Publicado: (2010) -
B cells tell scleroderma fibroblasts to produce collagen
por: Daoussis, Dimitrios, et al.
Publicado: (2013) -
A Case Report of Favourable Response of Polymyositis to Methotrexate Monotherapy
por: Daoussis, Dimitrios, et al.
Publicado: (2021)